Suppr超能文献

[天智颗粒治疗血管性认知障碍的疗效与安全性的系统评价和Meta分析]

[Systematic evaluation and Meta-analysis of efficacy and safety of Tianzhi Granules in treatment of vascular cognitive impairment].

作者信息

Wen-Yue H U, Zhen-Yun Han, Hua-Ping M A, Jing-Feng Lin, Ze Chang

机构信息

Beijing University of Chinese Medicine Beijing 100029, China.

出版信息

Zhongguo Zhong Yao Za Zhi. 2020 Oct;45(19):4766-4775. doi: 10.19540/j.cnki.cjcmm.20200309.501.

Abstract

Tianzhi Granules has effects in calming liver wind, nourishing liver and kidney and activating blood. At present, it is used for treatment of vascular cognitive impairment. However, its efficacy and safety remained to be verified. Therefore, this study aims to systematically analyze the efficacy and safety of Tianzhi Granules in the treatment of vascular cognitive impairment. CNKI, VIP, WanFang, SinoMed, PubMed and Cochrane Library, ClinicalTrials.gov were retrieved to screen out relevant randomized controlled trials about the effect of Tianzhi Granules on vascular cognitive impairment according to the inclusion criteria. Two researchers independently used the risk of bias assessment tool for quality assessment, and extracted and checked the data. Cochrane systematic evaluation software RevMan 5.3 was used for data analysis. Twenty-seven articles involving 2 741 subjects were included. The intervention measure was Tianzhi Granules alone, and the control measure was Western medicine alone or blank control. According to the results, Tianzhi Granules was better than blank control and brain metabolism promoter in clinical efficacy rate and improvement of MMSE score. And it was better than blank control and nimodipine in the improvement of event-related potential(ERP) P300. Within 3 months, Tianzhi Granules had better effects than Western medicine group and blank group, with a low incidence of adverse events. Tianzhi Granules can be recommended for clinical use. However, due to the low quality of the include literatures, these potential benefits need to be confirmed in future standardized clinical trials with a large sample size.

摘要

天智颗粒具有平肝息风、滋补肝肾、活血化瘀之功效。目前用于治疗血管性认知障碍。然而,其疗效和安全性仍有待验证。因此,本研究旨在系统分析天智颗粒治疗血管性认知障碍的疗效和安全性。检索中国知网、维普、万方、中国生物医学文献数据库、PubMed、Cochrane图书馆、ClinicalTrials.gov,根据纳入标准筛选出有关天智颗粒对血管性认知障碍疗效的相关随机对照试验。两名研究人员独立使用偏倚风险评估工具进行质量评估,并提取和核对数据。采用Cochrane系统评价软件RevMan 5.3进行数据分析。纳入27篇文章,涉及2741名受试者。干预措施为单纯使用天智颗粒,对照措施为单纯使用西药或空白对照。结果显示,天智颗粒在临床有效率和MMSE评分改善方面优于空白对照和脑代谢促进剂。在事件相关电位(ERP)P300改善方面优于空白对照和尼莫地平。在3个月内,天智颗粒的效果优于西药组和空白组,不良事件发生率较低。天智颗粒可推荐临床使用。然而,由于纳入文献质量较低,这些潜在益处需要在未来大样本的标准化临床试验中得到证实。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验